{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.4.', 'Recording and Follow-Up of Adverse Event and/or Serious Adverse Event', 'Adverse Event and Serious Adverse Event Recording', 'When an AE or SAE occurs, it is the responsibility of the Investigator to review all documentation', '(eg, hospital progress notes, laboratory reports, and diagnostics reports) related to the event. The', 'Investigator will then record all relevant AE/SAE information in the CRF.', \"It is not acceptable for the Investigator to send photocopies of the patient's medical records to Alexion\", 'or designee in lieu of completion of the AE/SAE report. If applicable, additional information such as', 'relevant medical records, should be submitted with a signed SAE cover page to Alexion Global', 'Pharmacovigilance (GPV) via ClinicalSAE@alexion.com or via Facsimile: + 1.203.439.9347. In this', 'case, all patient identifiers, with the exception of the patient number, will be redacted on the copies of', 'the medical records before sending to GPV.', 'The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or', 'other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will', 'be documented as the AE or SAE.', 'Assessment of Event Severity', 'The Investigator will make an assessment of intensity for each AE and SAE reported during the study and', 'assign it to 1 of the following categories from National Cancer Institute Common Terminology Criteria for', 'Adverse Events (CTCAE) v5.0, published 27 Nov 2017. Each CTCAE term is a Lowest Level Term (LLT)', 'per MedDRA. Each LLT will be coded to a MedDRA Preferred Term:', 'Grade 1: Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated)', 'Grade 2: Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate', 'instrumental ADL)', 'Grade 3: Severe (severe or medically significant, but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL)', 'Grade 4: Life-threatening (urgent intervention indicated)', 'Grade 5: Fatal (death related to AE)', 'Any change in the severity of an AE should be documented based on specific guidelines in the eCRF', 'Completion Guidelines.', 'Severity and seriousness must be differentiated: severity describes the intensity of an AE, while the term', 'seriousness refers to an AE that has met specific criteria for an SAE as described above.', 'Assessment of Causality', 'The Investigator is obligated to assess the relationship between the study drug and each occurrence', 'of each AE or SAE. An Investigator causality assessment must be provided for all AEs (both', 'nonserious and serious). This assessment must be recorded in the eCRF and on any additional', 'forms, as appropriate. The definitions for the causality assessments are as follows:', 'Not related (unrelated)', 'Related: Temporal relationship to the study drug. Other conditions (concurrent illness,', 'concurrent medication reaction, or progression/expression of disease state) do not appear', 'to explain the event; the event corresponds with the known pharmaceutical profile;', 'improvement on discontinuation; reappearance on rechallenge.', 'Adverse Event Recording', 'The Investigator will use clinical judgment to determine the relationship to the study drug.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as', 'well as the temporal relationship of the event to study drug administration will be considered and', 'investigated.', 'Page 75 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Adverse Event and Serious Adverse Event Recording', 'The expectedness and reporting criteria of an SAE will be determined by the Sponsor, based on', 'the Reference Safety Document. The Investigator will also consult the IB in his/her assessment.', 'There may be situations in which an SAE has occurred and the Investigator has minimal', 'information to include in the initial report to Alexion or designee. However, it is very important', 'that the Investigator always makes an assessment of causality for every event before the', 'initial transmission of the SAE data to Alexion GPV.', 'The Investigator may change his/her opinion of causality in light of follow-up information and', 'send a SAE follow-up report with the updated causality assessment.', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements.', 'Follow-up of Adverse Events and Serious Adverse Events', 'The Investigator is obligated to perform or arrange for the conduct of supplemental measurements', 'and/or evaluations as medically indicated or as requested by Alexion or designee to elucidate the', 'nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory', 'tests or investigations, histopathological examinations, or consultation with other health care', 'professionals.', 'If a patient dies during participation in the study or during a recognized follow-up period, the', 'Investigator will provide Alexion or designee with a copy of any postmortem findings including', 'histopathology, if available.', 'The site will enter new or updated SAE data into the electronic system as soon as it becomes', 'available, but no later than 24 hours. The Investigator will submit any updated SAE data to the GPV', 'within 24 hours of awareness of the information.', '10.3.5.', 'Reporting of Serious Adverse Events', 'Serious Adverse Event Reporting to Alexion or Designee via the RAVE Safety Gateway', 'All SAEs must be reported to Alexion GPV within 24 hours of the Investigator or site staff awareness.', 'These timelines for reporting SAE information to the Sponsor need to be followed for the initial SAE report', 'and for all follow-up SAE information.', 'The Investigator or designee must record the SAE data in the eCRF and verify the accuracy of the', 'information with corresponding source documents. The SAE report should be submitted electronically via', 'the RAVE Safety Gateway.', 'In the event that either the electronic data capture (EDC) or the RAVE Safety Gateway is unavailable at the', 'site(s), the SAE must be reported on the paper SAE Contingency Form accompanied by an Investigator', 'signed cover page. Facsimile transmission or email may be used in the event of electronic submission', 'failure.', 'For all SAEs, the Investigator must provide the following:', 'Appropriate and requested follow-up information in the time frame detailed below', 'Causality of the SAE(s)', 'Treatment of/intervention for the SAE(s)', 'Outcome of the SAE(s)', 'Supporting medical records and laboratory/diagnostic information', 'The primary mechanism for reporting an SAE to Alexion or designee will be the RAVE Safety', 'Gateway.', 'If the electronic system is unavailable at the time that the Investigator or site becomes aware of an', 'SAE, the site will use the paper Contingency Form for SAE reporting via facsimile or email.', 'Facsimile transmission or email may be used in the event of electronic submission failure.', 'Email: clinicalsae@alexion.com', 'Facsimile: + 1.203.439.9347', 'Page 76 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}